U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H15N3O2S
Molecular Weight 265.331
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALBENDAZOLE

SMILES

CCCSC1=CC=C2N=C(NC(=O)OC)NC2=C1

InChI

InChIKey=HXHWSAZORRCQMX-UHFFFAOYSA-N
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)

HIDE SMILES / InChI
Molecular Formula C12H15N3O2S
Molecular Weight 265.331
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11386684

ALBENZA (albendazole) is an orally administered anthelmintic drug. Chemically, it is methyl 5¬ (propylthio)-2-benzimidazolecarbamate, is indicated to treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. In addition, treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Albendazole binds to the colchicine-sensitive site of β-tubulin inhibiting their polymerization into microtubules. The decrease in microtubules in the intestinal cells of the parasites decreases their absorptive function, especially the uptake of glucose by the adult and larval forms of the parasites, and depletes glycogen storage. Insufficient glucose results in insufficient energy for the production of adenosine trisphosphate (ATP) and the parasite eventually dies. Albendazole developed in 1975. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just >1% . Albendazole's unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92%, for A. duodenale in 23 studies and 75% for N. americanus in 30 studies), A. lumbricoides (95% in 64 studies), T. trichiura (48% in 57 studies), E. vermicularis (98% in 27 studies), S. stercoralis (62% in 19 studies), H. nana (68% in 11 studies), and Taenia spp. (85% in 7 studies).

CNS Activity

CNS Penetrant
2523
Curator's Comment: Albendazole penetrates blood–brain barrier, with concentrations in CSF reaching 50% of that found in plasma

Originator

Approval Year

1989
121
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
ALBENZA

Approved Use

ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Launch Date

8.3445121E11
Curative
Approved
8360
ALBENZA

Approved Use

ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Launch Date

8.3445121E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
39.61 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1310 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
707.37 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
284.55 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3713.96 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.91 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
11.43 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
1200 mg 2 times / day multiple, oral
MTD
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
Page: p.600
unhealthy, 25–81
n = 9
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 25–81
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
Page: p.600
Disc. AE: Neutropenic sepsis...
AEs leading to
discontinuation/dose reduction:
Neutropenic sepsis (grade 5, 11%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
Page: p.600
3200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 3200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3200 mg, 1 times / day
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
Page: p.57-58
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Neurocysticercosis
Age Group: 38
Sex: F
Population Size: 1
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
Page: p.57-58
Disc. AE: Parkinsonism aggravated...
AEs leading to
discontinuation/dose reduction:
Parkinsonism aggravated
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
Page: p.57-58
16 g single, oral (total daily dose)
Overdose
Dose: 16 g
Route: oral
Route: single
Dose: 16 g
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.10
unhealthy
n = 1
Health Status: unhealthy
Condition: Hydatid Disease
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.10
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.10
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
Disc. AE: Granulocytopenia, Pancytopenia...
Other AEs: Bone marrow depression, Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Granulocytopenia (grade 5)
Pancytopenia (grade 5)
Other AEs:
Bone marrow depression
Aplastic anemia
Agranulocytosis
Disorder fetal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
Disc. AE: Hepatic dysfunction NOS...
AEs leading to
discontinuation/dose reduction:
Hepatic dysfunction NOS (3.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
Disc. AE: Leukopenia...
AEs leading to
discontinuation/dose reduction:
Leukopenia (0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
AEs

AEs

AESignificanceDosePopulation
Neutropenic sepsis grade 5, 11%
Disc. AE
1200 mg 2 times / day multiple, oral
MTD
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
Page: p.600
unhealthy, 25–81
n = 9
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 25–81
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
Page: p.600
Parkinsonism aggravated Disc. AE
3200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 3200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3200 mg, 1 times / day
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
Page: p.57-58
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Neurocysticercosis
Age Group: 38
Sex: F
Population Size: 1
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
Page: p.57-58
Agranulocytosis
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
Aplastic anemia
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
Bone marrow depression
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
Disorder fetal
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
Granulocytopenia grade 5
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
Pancytopenia grade 5
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.6
Hepatic dysfunction NOS 3.8%
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
Leukopenia 0.7%
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Page: p.9
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1709
substrate
1010
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1437
FMO
35

CYP
266

FMO3
66

CYP1A2
1032

CYP2E1
648

CYP2A6
523

CYP2B6
660

CYP2C8
688

CYP2C19
985

P-gp
1527

BCRP
555

MRP2
201

CYP2J2
56
CYP1A
56
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1626
 no
CYP1A
121
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2A6
523
 inconclusive
CYP2B6
660
 inconclusive
CYP2C19
985
 inconclusive
CYP2C8
688
 inconclusive
BCRP
555
 no
CYP2C9
1010
 no
CYP2E1
648
 no
MRP2
201
 no
MRP2
201
 no
ALBENDAZOLE sulfoxide
1
P-gp
1527
 no
P-gp
1527
 no
ALBENDAZOLE sulfoxide
1
BCRP
555
 yes
ALBENDAZOLE sulfoxide
1
CYP
266
 yes
CYP1A2
1032
 yes
CYP2J2
56
 yes
CYP3A4
1709
 yes
FMO
35
 yes
FMO3
66
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:16664
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16664
ChemicalBook
CB0241320
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0241320
MolPort
MolPort-000-726-929
https://www.molport.com/shop/molecule-link/MolPort-000-726-929
MolPort
MolPort-000-760-571
https://www.molport.com/shop/molecule-link/MolPort-000-760-571
MolPort
MolPort-001-932-918
https://www.molport.com/shop/molecule-link/MolPort-001-932-918
Selleck Chemicals
Albendazole(Albenza)
http://www.selleckchem.com/products/Albendazole(Albenza).html
ZINC
ZINC000017146904
http://zinc15.docking.org/substances/ZINC000017146904
eMolecules
1985404
https://www.emolecules.com/cgi-bin/more?vid=1985404
eMolecules
31777221
https://www.emolecules.com/cgi-bin/more?vid=31777221
eMolecules
534226
https://www.emolecules.com/cgi-bin/more?vid=534226
PubMed

PubMed

TitleDatePubMed
Comparison of worm control strategies in grazing sheep in Denmark.
2001
Albendazole therapy in the treatment of hydatid liver disease.
2001
Treatment of hydatid disease.
2001
In vitro taurocholate-induced segmentation and clustering of Mesocestoides vogae (syn. corti) tetrathyridia (Cestoda)--inhibition byh cestocidal drugs.
2001 Apr
Comparative metabolism of albendazole and albendazole sulphoxide by different helminth parasites.
2001 Apr
Subretinal cysticercosis.
2001 Apr
Echinococcosis of the spleen during pregnancy.
2001 Apr
Susceptibility of avian hosts to experimental Gymnophalloides seoi infection.
2001 Apr
A comparative study of different albendazole and mebendazole regimens for the treatment of intestinal infections in school children of Usigu Division, western Kenya.
2001 Apr
Extraocular muscle cysticercosis presenting as Brown syndrome.
2001 Apr
Pancreatitis secondary to Ascaris lumbricoides infestation.
2001 Apr
Ultrasound appearance of preclinical Oesophagostomum bifurcum induced colonic pathology.
2001 Apr
Microsporidiosis in the graft of a renal transplant recipient.
2001 Aug
Ivermectin treatment of a traveler who returned from Peru with cutaneous gnathostomiasis.
2001 Aug 15
Chemotherapy of enterobiasis (oxyuriasis).
2001 Feb
Pharmacotherapy of ascariasis.
2001 Feb
Echinococcus infestation of the splenius capitis.
2001 Feb
Non-invasive management of Ascaris lumbricoides biliary tact migration: a prospective study in 69 patients from Ecuador.
2001 Feb
Neurocysticercosis: an unusual presentation of a rare disease.
2001 Feb
Cardiac echinococcosis.
2001 Feb
Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination.
2001 Feb
Pharmacokinetics of netobimin and microsomal metabolism of albendazole in infected gerbils with Echinococcus granulosus.
2001 Feb
[Migrating swellings from Asia: gnathostomiasis].
2001 Feb 17
The effect of albendazole on Oesophagostomum bifurcum infection and pathology in children from rural northern Ghana.
2001 Jan
Pancreatitis due to Ascaris lumbricoides: second occurrence after 2 years.
2001 Jan
Recurrence of hydatid disease.
2001 Jan
Medical treatment of liver hydatidosis.
2001 Jan
Chronic diarrhea as a result of intestinal microsposidiosis in a liver transplant recipient.
2001 Jan 27
Gnathostomiasis.
2001 Jul 28
Strongyloides stercoralis eggs in the stools during anticancer therapy.
2001 Jul-Aug
Parasitic cysts of the liver - practical approach to diagnosis and differentiation.
2001 Jul-Aug
Treatment of ocular toxocariasis with albendazole.
2001 Jun
Intestinal helminth infections, anaemia and labour productivity of female tea pluckers in Bangladesh.
2001 Jun
Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up.
2001 Jun
The management of liver hydatid cysts by percutaneous drainage.
2001 Jun
Late onset temporal lobe epilepsy with MRI evidence of mesial temporal sclerosis following acute neurocysticercosis: case report.
2001 Jun
An unusual cause of renal colic: hydatiduria.
2001 Jun
Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome.
2001 Jun 15
Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract.
2001 Jun 19
[Response of multiorganic hydatdosis to combined therapy with albendazoleand praziquantel].
2001 Mar
Two imported cases of cutaneous larva migrans.
2001 Mar
Hepatobiliary and pancreatic ascariasis.
2001 Mar
Laparoscopic excision of splenic hydatid cyst.
2001 Mar
In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes.
2001 Mar-Apr
[Human microsporidiosis].
2001 May
Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen.
2001 May
The epidemiology of gastrointestinal nematodes of dairy cattle in central Kenya.
2001 May
Microsporidial keratoconjunctivitis in a healthy contact lens wearer without human immunodeficiency virus infection.
2001 May
Gongylonema infection of the mouth in a resident of Cambridge, Massachusetts.
2001 May 1
Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis.
2001 May-Jun
Patents

Patents

JP2007500004A
13

Sample Use Guides

In Vivo Use Guide
Patients weighing 60 kg or greater, 400 mg twice daily; less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). Hydatid disease: 28-day cycle followed by 14-day albendazole-free interval for a total of 3 cycles. Neurocysticercosis: 8 to 30 days.
Route of Administration: Oral
In Vitro Use Guide
The antiproliferative effect of Albendazole (ABZ) on parent PTX-sensitive 1A9 and PTX-resistant sub-line 1A9PTX22 cells (human ovarian cancer)were compared to those induced by colchicine and paclitaxel (PTX). Cells were exposed to drugs for 3 days (colchicine) or 5 days (ABZ and PTX). The results demonstrate the inhibitory effect on 1A9 and 1A9PTX22 cells by ABZ (IC50=237 nM ± 3.65 and 351 nM ± 90 respectively).
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:37:22 UTC 2023
Edited
by admin
on Wed Jul 05 22:37:22 UTC 2023
Record UNII
F4216019LN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALBENDAZOLE
EP   GREEN BOOK   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
albendazole [INN]
Common Name English
ALBENDAZOLE [USP-RS]
Common Name English
ALBENDAZOLE [USAN]
Common Name English
ALBENZA
Brand Name English
SK&F 62979
Code English
METHYL 5-(PROPYLTHIO)BENZIMIDAZOL-2-YLCARBAMATE
Systematic Name English
ALBENDAZOLE [MI]
Common Name English
ZENTEL
Brand Name English
METHYL N-(5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
Systematic Name English
ALBENDAZOLE [WHO-IP]
Common Name English
ALBENDAZOLE [EP MONOGRAPH]
Common Name English
ALBENDAZOLE [USP MONOGRAPH]
Common Name English
ALBENDAZOLE [VANDF]
Common Name English
SK&F-62979
Code English
Methyl 5-(propylthio)-2-benzimidazolecarbamate
Common Name English
ALBENDAZOLE [JAN]
Common Name English
CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER
Common Name English
ALBENDAZOLE [HSDB]
Common Name English
ALBENDAZOLE [GREEN BOOK]
Common Name English
ESKAZOLE
Brand Name English
ALBENDAZOLE [MART.]
Common Name English
Albendazole [WHO-DD]
Common Name English
ALBENDAZOLE [ORANGE BOOK]
Common Name English
ALBENDAZOLUM [WHO-IP]
Common Name English
ANDAZOL
Brand Name English
NSC-220008
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 94295
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.1.1
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
CFR 21 CFR 520.38A
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
WHO-ATC P02CA03
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
CFR 21 CFR 520.38
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
NCI_THESAURUS C250
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
WHO-VATC QP52AC11
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
CFR 21 CFR 520.38B
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
CFR 21 CFR 556.34
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
FDA ORPHAN DRUG 94195
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
LIVERTOX NBK548360
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
NDF-RT N0000175481
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.1.2
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
Code System Code Type Description
DAILYMED
F4216019LN
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
CHEBI
16664
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
FDA UNII
F4216019LN
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
MERCK INDEX
M1473
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY Merck Index
RS_ITEM_NUM
1012553
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
NSC
220008
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
HSDB
7444
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
PUBCHEM
2082
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
RXCUI
430
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB00518
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
SMS_ID
100000087712
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
CAS
54965-21-8
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
WIKIPEDIA
ALBENDAZOLE
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ALBENDAZOLE
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water; soluble in glacial acetic acid R; slightly soluble in acetone R, very slightly soluble in ethanol (~750 g/l) TS. Category: Anthelminthic. Storage: Albendazole should be kept in a well-closed container, protected from light. Additional information: Melting temperature, about 210?C, with decomposition. Requirement: Albendazole contains not less than 98.0% and not more than 101.0% of C12H15N3O2S, calculated with reference to the dried substance.
MESH
D015766
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
NDF-RT
N0000191624
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY Cytochrome P450 1A Inducers [MoA]
NCI_THESAURUS
C47384
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
INN
3967
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
EVMPD
SUB05295MIG
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
ChEMBL
CHEMBL1483
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
ALANWOOD
albendazole
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
DRUG CENTRAL
103
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
EPA CompTox
DTXSID0022563
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
LACTMED
Albendazole
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
ECHA (EC/EINECS)
259-414-7
Created by admin on Wed Jul 05 22:37:22 UTC 2023 , Edited by admin on Wed Jul 05 22:37:22 UTC 2023
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 3 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
Structure of ALBENDAZOLE OXIDE
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of ALBENDAZOLE-2-AMINO SULFONE
METABOLITE INACTIVE -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE OXIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of METHYL (5-CHLORO-2-BENZIMIDAZOLYL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(4,6-DICHLORO-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE-2-AMINO SULFONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of OXIBENDAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE SULFONE
IMPURITY -> PARENT
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE AMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(5-((2-METHYL-4-OXOPENTAN-2-YL)SULFANYL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-(S-METHYL) ALBENDAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE OXIDE
IMPURITY -> PARENT
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(5-(BUTYLSULFANYL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(5-((PROPAN-2-YL)SULFANYL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CARBENDAZIM
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of ALBENDAZOLE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966